Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
about
Risperidone (depot) for schizophreniaProfile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a reviewChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureProspective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.Long-acting atypical antipsychotics: characterization of the local tissue responseSchizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study).Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Olanzapine pamoate for the treatment of schizophrenia.A review of olanzapine pamoate.Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS).Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples.[Long-acting injectable antipsychotics. Overview and advice for daily routine care].
P2860
Q24185901-A0A0A664-C9DA-4779-B6FB-AB503528F3DAQ28084899-AC58FF91-E16C-4050-A49B-E695014D45A0Q28728401-60CFDBAA-F3F4-47E4-B207-D56A2261DA73Q34032665-E2889F52-F767-4BC3-A7B1-B90734104A93Q34130433-019B2FEF-2479-47F8-8C47-E50751E39026Q35895582-580DE03E-F43F-4F98-8898-2D0158F0848DQ36211694-DD95C7C5-83F7-4BEB-AC88-D6BE95B889A7Q37501165-96F7A299-6894-4DC3-804F-A9EB7EEA3BB1Q37831310-18FFD847-C064-4535-BB2A-3CDBE42E3371Q38022638-A0AEAAC3-5C7C-45E7-B481-43CEE5336F6DQ44228933-4EDADEAC-0A93-40A2-AC86-D0AB3B84C342Q45170470-8550D731-9FD4-44BE-BC0E-8E60F375BCD2Q46122791-4520067F-69C2-4C8F-97C8-406C4E52F02BQ52882243-C2E52398-FB0C-40CB-87FE-E3A6304CAAFD
P2860
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-acting atypical injectabl ...... afety and tolerability review.
@en
Long-acting atypical injectabl ...... afety and tolerability review.
@nl
type
label
Long-acting atypical injectabl ...... afety and tolerability review.
@en
Long-acting atypical injectabl ...... afety and tolerability review.
@nl
prefLabel
Long-acting atypical injectabl ...... afety and tolerability review.
@en
Long-acting atypical injectabl ...... afety and tolerability review.
@nl
P2860
P1476
Long-acting atypical injectabl ...... afety and tolerability review.
@en
P2093
Fernando Cañas
Hans-Jürgen Möller
P2860
P304
P356
10.1517/14740338.2010.506712
P407
P577
2010-09-01T00:00:00Z